Regenerative Injection denied as duplicate or overlapping therapy by Cigna?
If two medications appear duplicative on paper but serve different clinical purposes (e.g., short-acting vs long-acting), the appeal needs to spell out the clinical rationale for both.
US health-plan appeal rights
Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules
Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.
What Cigna typically requires
Cigna's specific coverage criteria for regenerative injection are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.
The Cigna angle on Regenerative Injection
## Why Cigna Denied Your Regenerative Injection as Duplicate Therapy
Cigna issues a duplicate-therapy denial when its reviewers conclude that a regenerative injection — such as platelet-rich plasma (PRP) or similar biologics — is providing the same clinical benefit as another treatment you are already receiving or have recently received. The logic is that paying for two therapies targeting the same condition with the same mechanism is not medically necessary. These denials are frequently overturned on appeal because the treatments in question often work through different mechanisms, are administered at different anatomical sites, or address distinct components of a complex diagnosis.
## Your Right to Appeal
Federal law gives you a layered appeal process:
- Internal appeal: Submit a formal written appeal to Cigna within the timeframe stated on your denial letter (commonly 180 days). Cigna must issue a decision within established regulatory deadlines.
- External review (ACA §2719): If the internal appeal fails, you have the right to an independent external review by an accredited Independent Review Organization (IRO). The external review window is generally available for up to four months after your final internal denial. If your condition is urgent, request expedited external review, which can produce a decision within 72 hours.
- ERISA §503: If your plan is employer-sponsored and governed by ERISA, you also have the right to a full-and-fair review and may pursue federal court review if the process is exhausted.
## Documentation to Gather
1. Diagnosis confirmation: Current records documenting the specific diagnosis, affected site, and clinical severity — imaging reports, examination findings, and functional assessments. 2. Treatment history with dates and outcomes: A complete list of every prior and current treatment, with start/stop dates and documented response or lack of response. This is the core evidence against a duplicate-therapy finding. 3. Mechanism differentiation: A letter from your prescribing clinician explaining how the regenerative injection differs mechanically or anatomically from any concurrent treatment, and why both are necessary. 4. Prescriber medical-necessity letter: A detailed letter from your provider stating that the therapies are not interchangeable, identifying what each one addresses, and citing the applicable clinical guideline organization (such as relevant orthopedic or pain-medicine society guidelines) that supports concurrent or sequential use.
## Criteria-Mapping Strategy
Pull the full text of Cigna's published medical policy for regenerative injections. List every criterion Cigna uses to define "duplicate therapy." For each criterion, document in writing exactly how your case does or does not meet it, citing the specific chart entry or clinician statement that supports your position. If the policy is silent on concurrent use with a specific co-treatment, note that gap — ambiguity in coverage policy is generally resolved in the member's favor under ERISA and ACA rules.
Aim to show that each treatment serves a distinct, documented clinical purpose that the other cannot fulfill.
Next steps
- Find the date on the denial letter — your appeal window starts there.
- Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
- Request the insurer's claim file in writing — they must provide it.
- Submit your appeal in writing with new clinical evidence and a physician statement.
Get the letter drafted
DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.
Start my appeal — $30 with code SEO25 →